Last reviewed · How we verify
Placebo plus Docetaxel
Docetaxel is a microtubule-stabilizing chemotherapy agent that disrupts cell division, combined with placebo as a control comparator.
Placebo plus Docetaxel, marketed by Infinity Pharmaceuticals, Inc., holds a position in the oncology segment without a specified primary indication. The key composition patent is set to expire in 2028, providing a clear timeline for potential generic competition. The lack of detailed revenue and trial results poses a significant risk in assessing the drug's market performance and therapeutic efficacy.
At a glance
| Generic name | Placebo plus Docetaxel |
|---|---|
| Also known as | Docetaxel, control group |
| Sponsor | Infinity Pharmaceuticals, Inc. |
| Drug class | Taxane (microtubule stabilizer) |
| Target | Microtubules (β-tubulin) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Docetaxel binds to and stabilizes microtubules, preventing their depolymerization and thereby blocking mitotic progression and inducing apoptosis in rapidly dividing cancer cells. The placebo component serves as a control arm in clinical trials. This combination is used to evaluate the efficacy of docetaxel in various cancer indications.
Approved indications
- Metastatic breast cancer
- Non-small cell lung cancer
- Prostate cancer
- Gastric cancer
- Head and neck cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Peripheral neuropathy
- Fatigue
- Nausea/vomiting
- Diarrhea
- Alopecia
- Fluid retention
Key clinical trials
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) (PHASE3)
- Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65). (PHASE3)
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension (PHASE3)
- Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC (PHASE2)
- Desloratadine to Prevent Taxane-induced Peripheral Neuropathy in Patients With Breast Cancer (PHASE2)
- Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) (PHASE3)
- Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4) (PHASE3)
- Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo plus Docetaxel CI brief — competitive landscape report
- Placebo plus Docetaxel updates RSS · CI watch RSS
- Infinity Pharmaceuticals, Inc. portfolio CI